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Abstract The objective of the present study is to determine
the factors associated with persistent fatigue in patients with
severe rheumatoid arthritis (RA) and good disease response to
6 months of tumour necrosis factor inhibitor therapy. Eligible
patients with either persistent (PF) or no fatigue (NF) were
compared. Using validated questionnaires and bivariate anal-
ysis, this cross-sectional survey explored if clinical character-
istics, pain, self-efficacy, sleep and mood/depression differed
between groups. Patients with PF (PF; NF) (n=28; 28) report-
ed significantly more overall pain (11.3±9.4 (0–33); 6.9±8.9
(0–33)), more recent and current pain intensity (41.4±26.6 (0–
80) 24.4±26.6 (0–100) and depression (11.8±7.5 (1–35); 8.2
±6.6 (0–26)), than the NF group. There was no significant
difference between groups in self-efficacy and both groups
experienced poor sleep quality (Pittsburgh Sleep Quality In-
dex >5). Despite having good disease response, the PF group
had significantly higher rheumatoid factor incidence, disease
activity score-28, early morning stiffness duration and lower
incidence of ever-failing disease-modifying anti-rheumatic
drugs than the NF group. These findings enhance the fatigue
literature in patients with RA prescribed tumour necrosis fac-
tor (TNF) inhibition therapy, identifying the potentially mod-
ifiable factors of pain and depression, previously demonstrat-
ed to be strongly associated with fatigue in non-biologic pop-
ulations. In addition, this study highlights the association be-
tween persistent fatigue and an on-going state of low disease
activity. This infers that more judicious disease management
could minimise the symptom burden of pain and depression
and consequentially fatigue.
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Fatigue is recognised as an important symptom in rheumatoid
arthritis (RA) by patients and clinicians [1–3]. While not yet
defined in clear terms, its multidimensional nature has been
identified [4, 5]. Studies have shown that the causes and con-
sequences of fatigue in RA can be attributed to illness-related
aspects, physical functioning, cognitive/emotional function-
ing and social aspects [6]. It is acknowledged that RA fatigue
likely results from a complex interplay between these factors
[5, 7] and requires further study to determine causation and
best management [3, 6, 7].
Debate around to what degree fatigue is a primary or sec-
ondary symptom of the autoimmune inflammatory process [8,
9] has occurred in parallel with the positive impact of biologic
drug therapies on disease management and patient-reported
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outcome [3, 8, 10], the Outcome MEasurement in
Rheumatology Clinical Trials (OMERACT) patient perspec-
tive initiative [1, 11, 12] and the international endorsement of
fatigue as a patient-centred outcome for inclusion in all patient
studies [2]. Despite this elevated status, from patients’ per-
spectives, fatigue remains unmanageable and professional
support remains rare [13].
The overarching aim of this study was to contribute to the
rational development of appropriate prevention and
management strategies for fatigue. This is contingent on iden-
tifying its drivers. Reasons for minimal insight into fatigue to
date include (i) a lack of data from longitudinal observational
studies exclusive to patients with RA, (ii) studies that were
either confined to patients with only mild to moderately active
disease [14] or (iii) studies that excluded populations from
biologic registers on the basis of disease severity [9]. While
researchers have identified key contributory factors, such as
pain, sleep, self-efficacy and mood [9, 15], none has reported
investigating the relevance of these factors in patients in dif-
ferent disease states of activity with differing fatigue levels,
especially in the context of modern biological therapies [3].
Defining persistent fatigue as patient-reported presence of
moderate or greater fatigue, the purpose of this study was to
examine the factors associated with persistent fatigue in pa-
tients with established RA despite demonstrating a good dis-
ease response to 6 months of tumour necrosis factor (TNF)
inhibitor therapy.
Methods
Study design and patient population This cross-sectional
single-site study used an observational, naturalistic compara-
tive design. The procedures followed in this study are in ac-
cordance with the ethical standards of the relevant Ethics and
Medical Research Committees and with the Helsinki Declara-
tion of 1975, as revised in 1983. The study population was
patients with (1) confirmed RA [16], (2) minimal age 18 years
and (3) who had demonstrated a moderate to good disease
response following 6 months of TNF inhibitor treatment for
moderate to high disease activity [8], according to the disease
activity score-28 (DAS28)-based European Union of Leagues
against Rheumatism (EULAR) Response Criteria (ERC) [17].
Patients were excluded from the study if they had a primary
diagnosis of fibromyalgia syndrome or chronic fatigue
syndrome.
The DAS28 is a standardised, composite outcome measure of
disease activity calculated using a four variable formula
(DAS28-4 (variable) (C-reactive protein (CRP))=0.56∗√
(TJC28, 28 joint count for tenderness)+0.28∗√(SJC28, 28
joint count for swelling)+0.36∗ln (CRP)+1)+0.014∗(GH,
patient global health assessment on a 0–10 numeric rating
scale)+0.96. The DAS28 is a continuous scale ranging from
0 to 9.4, indicating level of RA disease activity. DAS28 >5.1
reflects high disease activity, 5.1–3.2 reflects moderate disease
activity, and <3.2 indicates low disease activity. Remission is
achieved when a DAS28 score <2.6 is obtained. The ERC
calculates both the degree of reduction in DAS28 as well as
current DAS28 so as to classify individual patients into three
categories of disease response: good (DAS28 improvement of
>1.2), moderate (DAS28 improvement of >0.6–≤1.2) and
non-response (DAS28 improvement of <0.6) [17]. Using the
ERC, patients who had achieved at least a moderate improve-
ment in their DAS28 in response to 6-month TNF inhibition
therapy were identified.
To meet the analysis needs of this study, assuming a large
effect size (0.8), alpha of 0.05 and power of 0.80, a sample
size of 54 was required, with a minimum of 27 in each group
[18]. Given the small sample size, the exact p value with the Z
approximation test was reported; p values <0.05 were
regarded as statistically significant. Holm’s sequential
Bonferroni post hoc adjustment was used in the comparison
tests to prevent type 1 error [19].
Data collection
Purposive consecutive sampling was used to recruit patients
meeting the inclusion criteria over a period of 18 months.
Sociodemographic details, clinical characteristics and clinical
assessments of disease activity using the ACR core set of
outcome measures (28-swollen joint count, 28-tender joint
count, pain, patient global health assessment, functional as-
sessment using the Health Assessment Questionnaire Disabil-
ity Index (HAQ-DI) and biochemical acute phase reactant
measure, C-reactive protein (CRP)) [20], along with fatigue
levels, were derived from the case notes. In all scales, higher
scores indicated worst outcome. Following telephone contact
to inform patients of the study, questionnaires to assess pain,
self-efficacy, sleep, mood and depression were posted to eli-
gible participants enclosed with an invitation to partake in the
study, a consent form and a prepaid addressed envelope. All
persons gave their informed consent prior to their inclusion in
the study.
Data collection tools
The sociodemographic and clinical characteristics derived
from the case notes were gender, age, educational back-
ground, current smoking status, disease duration, rheumatoid
factor (RF), haemoglobin level, disease-modifying anti-rheu-
matic drug (DMARD) history and early morning stiffness
(EMS) duration inminutes. DAS28 and the derived ERCwere
the indices used to identify the study population.
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Fatigue Fatigue was measured using a standard validated
five-point verbal scale recording fatigue over the last week.
This scale has previously demonstrated good validity and sen-
sitivity in patients with RA [4]. Patients indicated their level of
fatigue as being the following: none, mild, moderate, severe
and very severe. These data were used to differentiate between
those with and without persistent fatigue,
Pain Pain was assessed using the multidimensional Short-
Form McGill Pain Questionnaire (SF-MPQ) [21]. It contains
five separate pain scores. The first three (i) a sensory descrip-
tor score of the pain experience, (ii) an affective descriptor
score of the pain experience and (iii) a composite total descrip-
tor score for pain over the past weekwere rated on a four-point
pain intensity scale (none (0)–severe (3). The remaining two
captured (iv) overall past week pain intensity using a 100-mm
visual analogue scale (VAS) and (v) current pain intensity
captured verbally using five descriptive terms (0 = ‘no pain’
to 5 = ‘excruciating’ pain). In this study, internal consistency
(Cronbach’s α 0.72) was found to be consistent with previous
values shown in RA and fibromyalgia populations
(Cronbach’s α 0.73 to 0.89) [22].
Self-efficacy Patient self-efficacy (SE) was measured using
the Arthritis Self-Efficacy Scales (ASES), incorporating three
subscales, which is extensively used in RA studies [23]. The
ASES includes 20 items scored separately on a Likert scale of
1 (very uncertain) to 10 (very certain) from which the overall
mean of the subscale items is derived and higher scores
indicate greater confidence or SE. The three subscales are as
follows: pain (five items), functioning (nine items) and other
symptoms of SE (six items). The derived internal consistency
(Cronbach’s α 0.79–0.84) was consistent with previously
reported values (Cronbach’s α 0.76 to 0.89) [24].
Sleep The Pittsburgh Sleep Quality Index (PSQI), a 19-item
self-rated questionnaire was used to measure seven different
components of sleep, duration, quality, number of arousals,
efficacy, disturbances, use of sleep medications and daytime
dysfunction during the previous month. Its suitability for use
in patients with RA is documented [25]. The PSQI has report-
ed high construct validity [26], sensitivity and specificity.
Scores range from 0 to 25; a total score of >5 is indicative of
sleep disturbances. In this study, internal consistency among
the seven component scores was somewhat lower (Cronbach’s
α 0.65) than that reported (Cronbach’s α 0.83) in generic
studies [26].
Mood Two separate scales were used to assess different
aspects of mood and depression. The Profile of Mood
States (POMS) short form, a widely used tool to assess
transient and distinct mood states, has been used in a
variety of RA fatigue studies [27]. This 37-item scale can be
scored into five subscales (tension-anxiety, depression-dejec-
tion, fatigue-inertia, confusion-bewilderment and vigour).
Each item is rated from 0—not at all to 4—extremely. Its
discriminant validity is supported by being consistently more
highly related to corresponding mood measures (for example,
sad and depressed) (mean r=66.6), than non-corresponding
mood scales (for example, vigour versus inertia) (mean r=
49.5), when compared with other scales [28]. Internal consis-
tency in this study using Cronbach’s α ranged from 0.54 to
0.86 across the six items.
The Beck Depression Inventory II (BDI-II), an extensively
tested and validated questionnaire, comprises a series of 21
questions developed to measure the intensity, severity and
depth of depression. Each question assesses a specific symp-
tom, 13 items assess psychological symptoms, and 8 items
assess physical symptoms. Each item uses a four-point scale
(0 to 3), and total score range is 0–63. A score of 0–13 is
considered minimal, 14–19 mild, 20–28 moderate and 29–
63 severe. Its appropriateness as a screening tool for depres-
sion in patients with RA has been demonstrated [29]. It has a
high construct validity (Cronbach’s α=(0.80) and discrimi-
nates between depressed and non-depressed groups [30].
Permission to use all scales was secured.
Analysis The sample was subdivided into two groups for
comparative purposes. Those who self-reported moderate or
greater fatigue at time of recruitment were labelled the persis-
tent fatigue group while those who reported mild or no fatigue
were labelled the no-fatigue group. To enhance sample homo-
geneity, the two groups were matched approximately for gen-
der, age and disease duration. Analysis was conducted using
the statistical package SPSS 16.0 for Windows. Numbers and
percentage counts were used to report nominal data (educa-
tion/smoking status/RF); mean and standard deviations were
reported on the normally distributed variables (DAS28) and
medians and range for skewed data such as haemoglobin (HB)
and early morning stiffness (EMS) duration. Inferential statis-
tics to test for differences between subgroup means included
chi-square, independent sample t tests and Mann-Whitney U
test as appropriate. The significance level was originally set at
0.05 and then subjected to a Holm’s sequential Bonferroni
adjustment as multiple tests which are indicated at the bottom
of the relevant table.
Results
Patient demographic and clinical details All eligible pa-
tients who were invited to take part in the study accepted
(n=64), and all patients gave their informed consent prior to
their inclusion in the study. Of these 64 patients, 47 % (n=28)
qualified as the persistent fatigue group. The other 53 % (n=
Clin Rheumatol (2015) 34:1857–1865 1859
Table 1 Sociodemographic and
clinical characteristics of patients
with good disease outcome and
either persistent or no fatigue
Patients characteristics Persistent fatigue No fatigue p value
n (study, control) n (valid %) n (valid %)
Female gendera (n=28, 28) 22 (79) 23 (82) ≤0.213
Age (mean±SD (range), years)b 58±11 (26–77) 58±11 (23–81) ≤0.716
(n=28,28)
Disease duration (mean±SD (range), years)b 14±11 (0–36) 14±12 (0–39) ≤0.949
(n=28, 28)
Smoking statusa Current 9 (32) 7 (29) ≤0.139
(n=27, 24)
Educational backgrounda Primary 7 (25) 4 (20)
(n=26, 21) Secondary 12 (43) 7 (35)
Third level 6 (21) 9 (45)
Rheumatoid factora Positive 15 (54) 4 (14)a =0.006*
(n=28, 28) Negative 13 (46) 23 (82)
Ever-failed DMARDa Yes 18 (64) 24 (86)a =0.036*
(n=28, 27) No 10 (36) 3 (11)
Ever-failed biologic No 0 0
(n=28, 28)
Haemoglobin levels (median (range), g/dl)
(n=22, 13) 6 months 13 (9–15) 13.4 (9–17) ≤0.452
HAQ-DI (mean±SD)
(n=26, 16) 6 months 1.11±(0.62) 0.76±(0.55) =0.07
Early morning stiffness duration (median, min)c
(n=27, 26) 6 months 10 (0–180) 10 (0–30) =0.001*
Swollen joint count (mean±SD)
(n=28, 16) 6 months 2.2±(2.9) 1.0±(1.7) <0.135
Tender joint count (mean±SD)
(n=28, 16) 6 months 3.2±(4.7) 1.0±(2.3) <0.028*
Pain (mean±SD)
(n=28, 16) 6 months 4.4±(2.2) 2.3±(1.0) <0.001*
Patient global health (mean±SD)
(n=28, 16) 6 months 4.9±(2.2) 2.3±(1.0) <0.0001*
C-reactive protein (mean±SD)c
(n=28, 16) 4 (0–42) 4 (0–27) <0.718
C-reactive protein n (%) 6 months
<2 2 (7.1) 1 (5.9)
<10 21 (75.0) 12 (70.6)
>10 5 (17.9) 4 (17.9)
DAS-28 (mean±SD, min-max)c




>3.2 15 (62.5) 1 (37.5)
<2.7 9 (7.1) 13 (92.9)
HAQ-DI Health Assessment Questionnaire Disability Index, DMARD disease-modifying anti-rheumatic drugs
*Significance at the <0.05
a Chi-square test.
b Independent sample t test
cMann-Whitney U test
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36) of patients demonstrated a good fatigue outcome, qualify-
ing as the no-fatigue group, from which 28 patients were pur-
posively selected based on age, gender and disease duration.
The majority of the patients were female. There was no sig-
nificant difference between the groups’ smoking status,
educational background or HB. Significantly higher
RF-positive status, EMS duration and mean DAS28 and a
significantly lower incident of ever failed a disease-modifying
anti-rheumatic drug (DMARD) were seen in the persistent
fatigue group. While the difference between groups for the
HAQ-DI was not statistically significant, it did exceed the
known minimal clinical important difference [31] (Table 1).
A significant difference between fatigue groups was dem-
onstrated in total pain experienced during the previous week
(u=0 241, p=0.021). Sensory (u=0 251, p=0.02), pain inten-
sity VAS (u=0 223, p=0.023) and current pain intensity sub-
scales (u=0 231, p=0.009) were also significant (Table 2).
The three subscales for SE pain, functioning and other
symptoms did not differ significantly between fatigue groups
(Table 3). There was no significant difference in the total sleep
score or the sleep subscales between groups (Table 4). There
was also no difference between groups in relation to use of
sleep medications. The sleep score greater than 5 recorded in
both groups was clinically indicative of poor sleep quality.
The mean BDI-II Score±SD (range) of 11.8±7.5 (1–35)
for the persistent fatigue group was shown to be statistically
different from that of the no-fatigue group 8.2±6.6 (0–26),
U=265 and exact p=0.037 (two-tailed). Total scores on the
BDI-II were in what is considered to be the mild (0–13) to
moderate range (14–19) for depression. Mean mood (POMS)
total scores or subscales did not differ significantly between
groups (Table 5).
Discussion
This study identified factors peculiar to patients with RA and
persistent fatigue, despite a good disease response to 6-month
TNF inhibitor therapy, by comparing those with persistent
fatigue to those with no fatigue. There were no significant
differences in key or minor characteristics between the groups
at initiation of TNF inhibitor treatment, as reported elsewhere
[8]. However, there were some statistically or clinically sig-
nificant differences in group characteristics at 6 months post-
initiation of TNF inhibitor therapy. The HAQ-DI did exceed
the known minimal clinical important difference between
groups even though this was not statistically significant [31].
This is an important observation, as functional health status is
repeatedly reported to influence fatigue outcome in RA [6,
32]. The proportion of patients within the persistent fatigue
group who were RF-positive was significantly greater than
that in the no-fatigue group. The persistent fatigue group also
reported significantly longer EMS duration; this finding is in
keeping with a published longitudinal study which showed a
significant association between stiffness on awakening and
higher fatigue [33]. Furthermore, qualitative study has shown
that patients regard the absence of stiffness as an important
criterion for remission [34]. The lower incidence of ever-
failing DMARDs found in the persistent fatigue group was
contrary to what might have been expected.
Table 2 Comparative analysis of pain experience in patients with good disease outcome and either persistent or no fatigue (Mann-Whitney U test)
Short-Form McGill Pain Questionnaire (SF-MPQ)
n (study, control) (scale range)
Persistent fatigue No fatigue
Descriptors (during last week) Mean±standard deviation (range) p value Level of significancea
Mean sensory (n=27, 28) (0–33) 8.0±6.4 (0–24) 5.2±6.5 (0–23) 0.02* 0.013
Mean affective (n=27, 28) (0–12) 2.7±3.3 (0–12) 1.8±2.8 (0–10) 0.235 0.05
A: Total descriptor score (n=27, 28) (0–45) 11.3±9.4 (0–33) 6.9±8.9 (0–33) 0.021* 0.016
B: Past week: VAS pain intensity
(n=27, 26) (0–100 mm)
41.4±26.6 (0–80) 24.4±26.6 (0–100) 0.023* 0.025
C: Current: pain intensity n (valid %) (n=27, 28)
No pain 3 (11) 9 (32) 0.009* 0.01
Mild 6 (22) 11 (39)
Discomforting 13 (48) 5 (18)
Distressing 3 (11) 2 (7)
Horrible 2 (7) 0
Excruciating 0 1 (3)
*Significant
a Level of significance as set using Holm’s sequential Bonferroni adjustment
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Inclusion criteria for this study specified the demonstration of
a moderate to good disease response to TNF inhibitor therapy,
according to the ERC, as opposed to a specific DAS28 target.
However, the mean DAS28 score (≈3.3) reflected a low disease
activity state for patients with persistent fatigue. However, the
statistically significant and even lower mean DAS28 score dem-
onstrated in 93 % of those with no fatigue reflected a state of
clinical remission (DAS28 <2.6) [17], versus only 37 % of the
persistent fatigue group. These data also indicate an association
between persistent fatigue and other unfavourable disease char-
acteristics [35], including a positive RF [36]. Assertions within
the literature suggest that DAS28 <2.6 is more representative of
minimal disease activity than of remission [37]. Overall, these
data show an association between persistent fatigue and an on-
going state of low disease activity. It therefore highlights the need
to look beyond disease remission for optimal disease manage-
ment to improve symptom burden and patient outcomes.
With respect to the patient-reported outcome, pain findings
confirm that in patients with disease severity which warranted
TNF inhibitor therapy, those with persistent fatigue experi-
enced more pain than those with no fatigue [3, 6, 38]. This
interrelationship was previously reported from studies with
either mixed diagnostic groups or non-biologic-treated popu-
lations [3, 9]. Further, the nature of this pain was reported to be
more physical in nature as opposed to being affective/
emotionally driven. Although the recent systematic review
of fatigue and factors related to fatigue in RA found conflict-
ing evidence with respect to the relationship between pain and
Table 3 Comparative analysis of arthritis self-efficacy in patients with good disease outcome and either persistent or no fatigue (Mann-WhitneyU test)
Subscales (range 1–10) (n=28) Persistent
fatigue
No fatigue
Mean±SD p value Significance
levela
Self-efficacy pain subscale:
How certain are you that you can…
1 Decrease your pain quite a bit? 5.9±2.0 6.1±3.0
2 Continue most of your daily activities? 6.5±2.5 6.9±2.9
3 Keep arthritis pain from interfering with your sleep? 6.1±3.0 6.7±2.8
4 Make small/moderate reduction in pain? 5.5±2.7 4.5±2.9
5 Make large reduction in your arthritis pain by using methods
other than taking extra medication?
4.3±2.7 4.8±3.2
Mean pain 5.6±1.9 6.1±2.3 0.359 0.025
Self-efficacy function subscale:
As of now how certain are you that you can
1 Walk 100 ft on flat ground in 20 s? 6.7±3.3 7.6±3.1
2 Walk ten steps downstairs in 7 s? 6.3±3.3 6.7±3.1
3 Get out of armless chair quickly without using your hands for support? 5.7±3.4 6.7±3.1
4 Button and unbutton three medium-size buttons in a row in 12 s? 6.8±3.1 7.7±2.4
5 Cut two bite-size pieces of meat with a knife and fork in 8 s? 6.8±3.2 7.5±2.7
6 Turn an outdoor tap all the way on and off? 6.6±2.9 6.8±3.1
7 Scratch your upper back with both your right and left hands? 5.1±3.3 5.8±3.3
8 Get in and out the passenger side of car without assistance from another
person and without physical aids?
7.2±25 7.7±2.9
9 Put on long-sleeved front-opening shirt or blouse (without buttoning) in 8 s? 7.2±2.9 8.2±2.5
Mean function 6.7±2.4 7.1±2.5 0.413 0.05
Self-efficacy other symptom subscale:
How certain are you that you can
1 Control your fatigue? 4.9±2.4 6.1±2.3
2 Regulate your activity so as to be active without aggravating your joints? 6.2±2.6 7.0±2.4
3 Do something to help yourself feel better if feeing blue? 6.1±2.7 7.4±2.7
4 Manage arthritis pain during daily activities? 6.4±2.8 7.2±2.5
5 Manage arthritis symptoms so that you can do the things you enjoy doing? 5.7±2.7 7.0±2.8
6 Deal with frustration of arthritis? 5.9±2.8 7.1±2.8
Mean other symptom 5.8±2.4 7.2±2.2 0.022 0.017
a Level of significance as set post-Holm’s sequential Bonferroni adjustment
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fatigue, nonetheless, pain was one of three variables with the
strongest evidence for a relationship with fatigue [6]; this
study supports the dominant interrelationship between pain
and fatigue. As patients in this study had demonstrated a good
disease response to 6 months of TNF inhibitor treatment at
time of assessment, these findings in a new treatment group
add to the body of evidence of previous work illustrating that
physical pain is a more important driver of persistent fatigue in
RA than is inflammation [3, 38, 39]. This study result there-
fore underscores why proactive pain management should con-
tinue to be a priority in comprehensive patient care.
SE as a previously reported contributor to fatigue [6] was not
substantiated by this study. In a previous systematic review, five
studies, undertaken in largely non-biologic populations, support-
ed SE and only one demonstrated no interrelationship between
SE and fatigue [6]. Nonetheless, as in this current study, the
systematic review failed to demonstrate that SE majorly influ-
enced fatigue status in RA. This current lack of association may,
in part, be explained by the superior clinical efficacy of biologic
medications.
This study found that patients with persistent fatigue had
significantly more depression than those with no fatigue. While
published evidence is conflicting with respect to the contribution
of depression towards the symptom of fatigue in RA; nonethe-
less, strong evidence of a relationship between these two symp-
toms exists [6]. While this association between fatigue and de-
pression is recognised in RA [6], so too is the existence of a
bidirectional causal pathway [40]. One previous study found a
steep increase in depression as functional limitation increased
[41], while another TNF inhibition study in RA showed that both
fatigue and pain significantly impacted on changes in depression
status and that clinical remission improved symptoms of depres-
sion [42]. There is a risk that the interrelationship between pain
and fatigue [43] is minimised by some literature that highlights
themediating effect ofmood disorders [6].With respect to symp-
tom management for this patient group, such an assumption
could result in suboptimal pain and fatigue management. More-
over, physiological pain and depression, identified as problem-
atic within the persistent fatigue group, are potential modifiable
drivers of fatigue.
Similar patient numbers per subgroup used sleep-inducing
medication, and both groups experienced a poor sleep quality.
In keeping with previous work [44], this was attributed to
physical discomforts, namely, that joint pain and limitation
Table 4 Pittsburgh Sleep Quality
Index (PSQI): comparative
analysis of sleep quality in
patients with good disease
outcome and either persistent or
no fatigue (Mann-Whitney U
test).




Mean±SD (range) (0–3) p value
Sleep duration (0–3) 1.1±1.1 (0–3) 0.6±0.9 (0–3) 0.061
Sleep disturbance (0–3) 1.5±1.0 (0–3) 1.5±0.8 (0–3) 0.901
Sleep latency (0–3) 1.4±1.1 (0–3) 1.3±1.0 (0–3) 0.856
Daytime dysfunction(0–3) 1.2±1.0 (0–3) 1.0±0.8 (0–3) 0.805
Sleep efficiency (0–3) 1.4±1.2 (0–3) 1.2±1.1 (0–3) 0.808
Overall sleep quality (0–3) 1.2±1.2 (0–3) 1.0±0.9 (0–3) 0.832
Sleep medications (0–3) 0.7±1.2 (0–3) 0.5±0.9 (0–3) 0.966
Total PSQI (0–21) 8.3±3.6 (4–16) 7.3±4.5 (0–18) 0.319
Table 5 Comparative analysis of mood and depression in patients with good disease outcome and either persistent or no fatigue (Mann-Whitney U
test)
Profile of mood states (range) Persistent fatigue No fatigue
Mean (SD), range n=28 p value
Depression-dejection (0–32) 4.8±5.4 (0–19) 3.3±5.2 (0–20) 0.102
Vigour-activity (0–24) 7.0±5.6 (0–18) 8.5±5.7 (0–20) 0.293
Anger-hostility (0–28) 3.9±4.5 (0–18) 2.4±2.9 (0–9) 0.134
Tension-anxiety (0–24) 4.1±3.8 (0–13) 3.6±4.3 (0–16) 0.351
Confusion-bewilderment (0–20) 2.1±1.9 (0–8) 2.1±3.0 (0–10) 0.324
Fatigue-inertia (0–20) 5.7±4.9 (0–20) 5.6±5.8 (0–21) 0.469
POMS Total (0–100) 13.7±19.8 (14–59) 8.6±18.4 (18–49) 0.306
Beck Depression Inventory (BDI) n=28 n=28
Level of depression (0–63) 11.8±7.5 (1–35) 8.2±6.6 (0–26) 0.037*
*Significant at <0.05 level
Clin Rheumatol (2015) 34:1857–1865 1863
due to pain mediated the association between arthritis and
insomnia [45]. However, findings from this study do not sug-
gest any association between persistent post-treatment fatigue
and sleep quality.
It is important to highlight study limitations inherent in a
naturalistic study design. This study was conducted in a real-
life clinical situation with an inability to address completeness of
data and study attrition. Study replication sufficiently powered
to support multiple regression analysis is recommended. Further,
the comparative study of persistent post-treatment fatigue was
restricted to the single disease entity of RA. While a high re-
sponse rate was achieved, the generalisation of results to non-RA
patients is not appropriate. It is also acknowledged that the
uniqueness of a single-site academic centre which had poor rep-
resentation of minority groups restricts the representativeness of
findings. Data on possible confounding variables such as daily
physical activities, physical exercise capacity, thyroid function
and morning (08.00 h) adrenocorticotropic hormone (ACTH)/
cortisol values was not collected. This comparative study adds
further to the body of knowledge on factors related to persistent
fatigue in patients with RA [6, 7] and to the limited body of
knowledge with respect to fatigue in TNF inhibitor-treated pa-
tients [3, 32]. It firmly highlights potential modifiable factors to
improve fatigue, namely, pain and depression. In addition, it
highlights the association between persistent fatigue and an on-
going state of low disease activity. This infers that more judicious
disease management could minimise the symptom burden of
pain and depression and consequentially fatigue.
Compliance with Ethical Standards This human study was approved
by the appropriate ethics committees and has therefore been performed in
accordance with the ethical standards laid down in the 1964 Declaration
of Helsinki and its later amendments. All persons gave their informed
consent prior to their inclusion in the study.
Disclosures None.
Funding This study was supported by a Health Research Board of Ireland
National Council for Nursing andMidwifery Junior Clinical Scientist Award.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Kirwan JR,Minnock P, Adebajo A, Bresnihan B, ChoyE, deWitM
et al (2007) Patient perspective: fatigue as a recommended patient
centered outcome measure in rheumatoid arthritis. J Rheumatol 34:
1174–1177
2. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M,
Bombardier C et al (2008) Reporting disease activity in clinical
trials of patients with rheumatoid arthritis: EULAR/ACR collabo-
rative recommendations. Ann Rheum Dis 67:1360–1364
3. Campbell RC, Batley M, Hammond A, Ibrahim F, Kingsley G,
Scott DL (2012) The impact of disease activity, pain, disability
and treatments on fatigue in established rheumatoid arthritis. Clin
Rheumatol 31:717–722
4. Hewlett S, Hehir M, Kirwan JR (2007) Measuring fatigue in rheu-
matoid arthritis: a systematic review of scales in use. Arthritis
Rheum 57:429–439
5. Nicassio PM, Ormseth SR, Custodio MK, Irwin MR, Olmstead R,
Weisman MH (2012) A multidimensional model of fatigue in pa-
tients with rheumatoid arthritis. J Rheumatol 39:1807–1813
6. Nikolaus S, Bode C, Taal E, van de Laar MA (2013) Fatigue and
factors related to fatigue in rheumatoid arthritis: a systematic re-
view. Arthritis Care Res (Hoboken) 65:1128–1146
7. Hewlett S, Chalder T, Choy E, Cramp F, Davis B, Dures E et al
(2011) Fatigue in rheumatoid arthritis: time for a conceptual model.
Rheumatology (Oxford) 50:1004–1006
8. Minnock P, McKee G, Bresnihan B, FitzGerald O, Veale DJ (2014)
How much is fatigue explained by standard clinical characteristics
of disease activity in patients with inflammatory arthritis? A longi-
tudinal study. Arthritis Care Res (Hoboken) 66:1597–1603
9. Bergman MJ, Shahouri SS, Shaver TS, Anderson JD, Weidensaul
DN, Busch RE et al (2009) Is fatigue an inflammatory variable in
rheumatoid arthritis (RA)?Analyses of fatigue in RA, osteoarthritis,
and fibromyalgia. J Rheumatol 36:2788–2794
10. Wolfe F, Michaud K (2004) Fatigue, rheumatoid arthritis, and anti-
tumor necrosis factor therapy: an investigation in 24,831 patients. J
Rheumatol 31:2115–2120
11. Minnock P, Kirwan J, Bresnihan B (2009) Fatigue is a reliable,
sensitive and unique outcome measure in rheumatoid arthritis.
Rheumatology (Oxford) 48:1533–1536
12. Nicklin J, Cramp F, Kirwan J, Urban M, Hewlett S (2010)
Collaboration with patients in the design of patient-reported out-
come measures: capturing the experience of fatigue in rheumatoid
arthritis. Arthritis Care Res (Hoboken) 62:1552–1558
13. Repping-Wuts H, van Riel P, van Achterberg T (2008)
Rheumatologists’ knowledge, attitude and current management
of fatigue in patients with rheumatoid arthritis (RA). Clin
Rheumatol 27:1549–1555
14. Repping-Wuts H, Fransen J, van Achterberg T, Bleijenberg G, van
Riel P (2007) Persistent severe fatigue in patients with rheumatoid
arthritis. J Clin Nurs 16:377–383
15. van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P (2010)
Physical and psychosocial correlates of severe fatigue in rheuma-
toid arthritis. Rheumatology (Oxford) 49:1294–1302
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF,
Cooper NS et al (1988) The American Rheumatism Association
1987 revised criteria for the classification of rheumatoid arthritis.
Arthritis Rheum 31:315–324
17. Fransen J, van Riel PL (2005) The Disease Activity Score and the
EULAR response criteria. Clin Exp Rheumatol 23:S93–S99
18. Faul FEE, Buchner A, Lang A-G (2009) Statistical power analyses
using G*Power 3.1: tests for correlation and regression analyses.
Behav Res Methods 41:1149–1160
19. Holm S (1979) A simple sequentially rejective multiple test proce-
dure. Scand J Stat 6:65–70
20. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D,
Goldsmith C et al (1995) American College of Rheumatology.
Preliminary definition of improvement in rheumatoid arthritis.
Arthritis Rheum 38:727–735
21. Melzack R, Katz J (eds) (2001) The McGill Pain Questionnaire:
appraisal and current status. The Guilford Press, New York
1864 Clin Rheumatol (2015) 34:1857–1865
22. Burckhardt CS, Bjelle A (1994) A Swedish version of the short-
form McGill pain questionnaire. Scand J Rheumatol 23:77–81
23. Brady TJ (2011) Measures of self-efficacy: Arthritis Self-Efficacy
Scale (ASES), Arthritis Self-Efficacy Scale-8 Item (ASES-8),
Children’s Arthritis Self-Efficacy Scale (CASE), Chronic Disease
Self-Efficacy Scale (CDSES), Parent’s Arthritis Self-Efficacy Scale
(PASE), and Rheumatoid Arthritis Self-Efficacy Scale (RASE).
Arthritis Care Res (Hoboken) 63(Suppl 11):S473–S485
24. Lorig K, Chastain RL, Ung E, Shoor S, Holman HR (1989)
Development and evaluation of a scale to measure perceived self-
efficacy in people with arthritis. Arthritis Rheum 32:37–44
25. Wells GA, Li T, Kirwan JR, Peterson J, Aletaha D, Boers M et al
(2009) Assessing quality of sleep in patients with rheumatoid ar-
thritis. J Rheumatol 36:2077–2086
26. Carpenter JS, Andrykowski MA (1998) Psychometric evaluation of
the Pittsburgh Sleep Quality Index. J Psychosom Res 45:5–13
27. Belza BL (1995) Comparison of self-reported fatigue in rheumatoid
arthritis and controls. J Rheumatol 22:639–643
28. Nyenhuis DL, Yamamoto C, Luchetta T, Terrien A, Parmentier A
(1999) Adult and geriatric normative data and validation of the
profile of mood states. J Clin Psychol 55:79–86
29. Krug HE, Woods SR, Mahowald ML (1997) The importance of
identifying depression in patients with rheumatoid arthritis: evalua-
tion of the beck depression inventory. J Clin Rheumatol 3:248–257
30. Beck AT, Steer RA, Carbin MG (1988) Psychometric properties of
the Beck Depression Inventory: twenty-five years of evaluation.
Clin Psychol Rev 8:77–100
31. Pope JE, Khanna D, Norrie D, Ouimet JM (2009) The minimally
important difference for the health assessment questionnaire in
rheumatoid arthritis clinical practice is smaller than in randomized
controlled trials. J Rheumatol 36:254–259
32. Druce KL, Jones GT, Macfarlane GJ, Basu N (2015) Patients re-
ceiving anti-TNF therapies experience clinically important im-
provements in RA-related fatigue: results from the British Society
for Rheumatology Biologics Register for Rheumatoid Arthritis.
Rheumatology (Oxford) 54:964–971
33. Stone AA, Broderick JE, Porter LS, Kaell AT (1997) The experi-
ence of rheumatoid arthritis pain and fatigue: examining momen-
tary reports and correlates over one week. Arthritis Care Res 10:
185–193
34. van Tuyl LH, Lems WF, Boers M (2014) Measurement of stiffness
in patients with rheumatoid arthritis in low disease activity or re-
mission: a systematic review. BMC Musculoskelet Disord 15:28
35. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P,
Gaujoux-Viala C et al. (2010) EULAR recommendations for the
management of rheumatoid arthritis with synthetic and biological
disease-modifying antirheumatic drugs. Ann Rheum Dis.
36. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De
Benedetti F et al (2011) Updated consensus statement on biological
agents for the treatment of rheumatic diseases, 2010. Ann Rheum
Dis 70(Suppl 1):i2–i36
37. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS
(2005) Remission and active disease in rheumatoid arthritis: defining
criteria for disease activity states. Arthritis Rheum 52:2625–2636
38. Minnock P, Bresnihan B (2008) Fatigue is related to poor pain
outcomes in women with established rheumatoid arthritis. Clin
Exp Rheumatol 26:707–708
39. Druce KL, Jones GT, Macfarlane GJ, Basu MN. (2015)
Determining pathways to improvements in rheumatoid arthritis
fatigue: results from the BSRBR-RA. Arthritis Rheumatol .
40. Wolfe F, Michaud K (2009) Predicting depression in rheumatoid
arthritis: the signal importance of pain extent and fatigue, and co-
morbidity. Arthritis Rheum 61:667–673
41. Margaretten M, Barton J, Julian L, Katz P, Trupin L, Tonner C et al
(2011) Socioeconomic determinants of disability and depression in
patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 63:
240–246
42. Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A
(2011) Improvements in patient-reported outcomes, symptoms of
depression and anxiety, and their association with clinical remission
among patients with moderate-to-severe active early rheumatoid
arthritis. Rheumatology (Oxford) 50:401–409
43. van Dartel SA, Repping-Wuts JW, van Hoogmoed D, Bleijenberg
G, van Riel PL, Fransen J (2013) Association between fatigue and
pain in rheumatoid arthritis: does pain precede fatigue or does fa-
tigue precede pain? Arthritis Care Res (Hoboken) 65:862–869
44. Louie GH, Tektonidou MG, Caban-Martinez AJ, Ward MM
(2011) Sleep disturbances in adults with arthritis: prevalence,
mediators, and subgroups at greatest risk. Data from the
2007 National Health Interview Survey. Arthritis Care Res
(Hoboken) 63:247–260
45. Minnock P. (2011) Mixed methods research design to determine
clinical characteristics, contributory factors and patients’ percep-
tions of fatigue in inflammatory arthritis. School of Nursing and
Midwifery. [PhD Thesis], Dublin: Trinity College Dublin.
Clin Rheumatol (2015) 34:1857–1865 1865
